P values calculated from independent samples t tests (two-tailed, equal variance not assumed) for tumor volume, tumor FAZA uptake, and tumor hypoxic fraction parameters at various study time points.
Statistically significant difference in tumor FAZA uptake (expressed both in terms of %ID/g and tumor hypoxic fraction) is found on day 7 post-treatment initiation between the nal-IRI (10 mg/kg) and the other two treatment groups. Statistically significant difference in tumor volume, for the same groups, is seen on day 10 and 16. A total of 10 tumors were included in the analysis for each group on days 4 through 16. On day 21, the number of tumors per group was 4, 6, and 8 for irinotecan, nal-IRI (10 mg/kg) and nal-IRI (5 mg/kg), respectively